The stock of Cellebrite DI Ltd (CLBT) has gone up by 1.63% for the week, with a -5.64% drop in the past month and a -21.20% drop in the past quarter. The volatility ratio for the week is 2.19%, and the volatility levels for the past 30 days are 1.66% for CLBT. The simple moving average for the last 20 days is -0.41% for CLBT stock, with a simple moving average of -15.44% for the last 200 days.
Is It Worth Investing in Cellebrite DI Ltd (NASDAQ: CLBT) Right Now?
The 36-month beta value for CLBT is also noteworthy at 1.31. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CLBT is 108.96M, and at present, short sellers hold a 0.98% of that float. The average trading volume of CLBT on June 26, 2025 was 1.26M shares.
CLBT) stock’s latest price update
Cellebrite DI Ltd (NASDAQ: CLBT)’s stock price has decreased by -0.12 compared to its previous closing price of 16.26. However, the company has seen a 1.63% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-24 that TYSONS CORNER, Va., June 24, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the expansion of its relationship with the National Center for Missing and Exploited Children (NCMEC) that will help speed up investigations involving crimes against children. NCMEC’s CyberTipline hash value list is now integrated within Cellebrite’s flagship digital forensics software, Cellebrite Inseyets, allowing public safety agencies to immediately pinpoint known child sexual abuse material (CSAM) files – speeding up time to evidence and justice for victims and survivors of abuse. The hash value list contains approximately 10-million files reported by electronic service providers to NCMEC, which have been confirmed to depict apparent CSAM.
Analysts’ Opinion of CLBT
Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the previous year 2024.
BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the previous year.
CLBT Trading at -8.65% from the 50-Day Moving Average
After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.25% of loss for the given period.
Stock Fundamentals for CLBT
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.84 for the gross margin
The net margin for Cellebrite DI Ltd stands at -0.46. The total capital return value is set at 0.14. Equity return is now at value -115.35, with -31.35 for asset returns.
Based on Cellebrite DI Ltd (CLBT), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 13.49. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 0.23.
Currently, EBITDA for the company is 67.51 million with net debt to EBITDA at -1.13. When we switch over and look at the enterprise to sales, we see a ratio of 9.09. The receivables turnover for the company is 5.17for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
In summary, Cellebrite DI Ltd (CLBT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
